Retatrutide (also referred to as LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
This stability has not gone unnoticed, attracting significant interest from private equity firms and even traditional pharmaceutical manufacturers like Hikma, which announced plans to expand into the 503B sector
Because the keto diet is high in fat, combining them may cause unpleasant side effects such as oily stools, stomach cramps and urgency
Walking, resistance training, swimming, cycling, or low-impact movement can help preserve muscle mass and support cardiometabolic health during weight loss
reported that GLP-1-induced suppression of glucagon release is dependent of protein kinase A (PKA) and independent of glucose or paracrine effects mediated by insulin or by somatostatin acting on somatostatin receptor subtype-2 [16],[17]
These compounds are designed to influence glucose regulation, appetite, and lipid metabolism for laboratory research use only or equivalent